Given the significance of immune checkpoint molecule expression in predicting immunotherapy response, the correlation between EZH2 and expression levels of seven common immune checkpoint molecules (i.e., BTLA, CD276, LAG3, PD-1, PD-L1, PD-L2, and CTLA4) in TCGA pan-cancer cohort was tested to explore the potential value of EZH2 in immunotherapy [66]. This evidence concerns the gene PDCD1LG2 and cancer.